Modality
siRNA
MOA
PCSK9i
Target
FXIa
Pathway
Complement
IPF
Development Pipeline
Preclinical
~Jan 2022
→ ~Apr 2023
Phase 1
Jul 2023
→ Apr 2031
Phase 1Current
NCT06877802
1,185 pts·IPF
2025-11→2026-12·Terminated
NCT06377155
2,907 pts·IPF
2023-07→2031-04·Not yet recruiting
4,092 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-128mo awayInterim· IPF
2031-04-205.1y awayInterim· IPF
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Not yet…
P1
Termina…
Catalysts
Interim
2026-12-12 · 8mo away
IPF
Interim
2031-04-20 · 5.1y away
IPF
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06877802 | Phase 1 | IPF | Terminated | 1185 | Mayo |
| NCT06377155 | Phase 1 | IPF | Not yet recr... | 2907 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Rimaosocimab | Amgen | Preclinical | FXIa |